公开(公告)号：US11896031B2

公开(公告)日：2024-02-13

申请号：US17581535

申请日：2022-01-21

Applicant: THE SOUTH DAKOTA BOARD OF REGENTS, AS GOVERNING BOARD FOR SOUTH DAKOTA STATE UNIVERSITY

Inventor： William Gibbons ,  Michael Brown

IPC: A23K40/25 ,  A23J1/12 ,  A23K40/20 ,  A23K10/14 ,  A23K50/80 ,  A23J1/14 ,  A23K20/147 ,  A23K10/38

CPC classification number: A23J1/125 ,  A23J1/14 ,  A23J1/148 ,  A23K10/14 ,  A23K10/38 ,  A23K20/147 ,  A23K40/20 ,  A23K40/25 ,  A23K50/80 ,  Y02A40/818

Abstract: The present invention describes a bio-based process to produce high quality protein concentrate (HQPC) by converting plant derived celluloses into bioavailable protein via aerobic incubation, including the use of such HQPC so produced as a nutrient, including use as a fish meal replacement in aquaculture diets.

公开(公告)号：US11684661B2

公开(公告)日：2023-06-27

申请号：US16858924

申请日：2020-04-27

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  SOUTH DAKOTA STATE UNIVERSITY

Inventor： David A. Sack ,  Weiping Zhang

IPC: A61K39/108 ,  C07K14/245 ,  A61K39/08 ,  A61K45/06 ,  A61K39/00

CPC classification number: A61K39/0258 ,  A61K39/08 ,  A61K45/06 ,  C07K14/245 ,  A61K2039/575 ,  A61K2039/6037 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/55

Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STatoxoid-LTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.

公开(公告)号：US11016118B2

公开(公告)日：2021-05-25

申请号：US16766228

申请日：2018-11-23

Applicant: SOUTH DAKOTA STATE UNIVERSITY

Inventor： Qiquan Qiao ,  Behzad Bahrami ,  Ashraful Haider Chowdhury

IPC: G01Q60/30 ,  G01Q60/38

Abstract: A system for conductive atomic force microscopy measurements includes a function generator that drives a light source as well as current provided to a sample, designed sample holder for local charge dynamics measurements and output circuitry that includes both a frequency response analysis as well as a bypass circuit analysis portion. Bypass circuit with external preamplifier helped to overcome the obstacles of commercially available AFM circuit bandwidth (e.g. 100 kHz) to see the local characteristics with high temporal resolution. By obtaining the data output of the frequency response analyzer and the bypass circuitry, local mobility map, local carrier lifetime and transport time map, local carrier density map, and a nanoscale impedance map can be made of complex solid state devices at high temporal and spatial resolutions.

公开(公告)号：US20200306354A1

公开(公告)日：2020-10-01

申请号：US16858924

申请日：2020-04-27

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  SOUTH DAKOTA STATE UNIVERSITY

Inventor： David A. Sack ,  Weiping Zhang

IPC: A61K39/108 ,  C07K14/245 ,  A61K39/08 ,  A61K45/06

Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STatoxoid-LTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.

公开(公告)号：US10646560B2

公开(公告)日：2020-05-12

申请号：US15105195

申请日：2014-12-17

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  SOUTH DAKOTA STATE UNIVERSITY

Inventor： David A. Sack ,  Weiping Zhang

IPC: A61K39/108 ,  C07K14/245 ,  A61K39/08 ,  A61K45/06 ,  A61K39/00

Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STa-toxoidLTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.

公开(公告)号：US20160235082A1

公开(公告)日：2016-08-18

申请号：US15046034

申请日：2016-02-17

Applicant: South Dakota State University

Inventor： Hasmukh Ambalal PATEL ,  Suresh Ganpatbhai SUTARIYA

IPC: A23C3/08 ,  A23C21/00 ,  A23J3/08 ,  A23C3/033

CPC classification number: A23C3/085 ,  A23C3/033 ,  A23C21/00 ,  A23J3/08 ,  A23V2002/00 ,  A23V2250/152 ,  A23V2250/54252

Abstract: Different versions of heat stable whey protein ingredients can be produced by subjecting whey protein solutions to specific heat treatments in the presence of a specific concentration of hydrogen peroxide. The whey protein ingredients including heat stable liquid retentate of WPI, WPC or any other form of whey protein ingredients, and heat stable powders of WPI or WPC or any other whey protein powders can be prepared by heat treatment of a whey protein solution mixed with a hydrogen peroxide solution. The heat stable whey proteins have the starting whey protein cystine converted to cystine sulfonic acid, such that the free sulfhydral groups of major whey protein (β-lactoglobulin) being converted into non-reactive compounds, such as cysteine sulphonic acid and/or cysteic acid, which not only minimizes or eliminates undesirable gelling but also is a precursor for taurine group of compounds.

Abstract translation: 可以通过在特定浓度的过氧化氢存在下对乳清蛋白溶液进行比热处理来制备不同形式的热稳定乳清蛋白成分。 包括WPI，WPC或任何其他形式的乳清蛋白成分的热稳定性液体滞留物的乳清蛋白成分以及WPI或WPC或任何其它乳清蛋白粉末的热稳定粉末可以通过热处理与 过氧化氢溶液。 热稳定的乳清蛋白将起始的乳清蛋白质胱氨酸转化为胱氨酸磺酸，使主要乳清蛋白（β-乳球蛋白）的游离巯基转化为非反应性化合物，如半胱氨酸磺酸和/或半胱氨酸 ，其不仅最小化或消除不期望的胶凝，而且还是牛磺酸基化合物的前体。

公开(公告)号：US09616021B2

公开(公告)日：2017-04-11

申请号：US14203476

申请日：2014-03-10

Applicant: South Dakota State University

Inventor： Omathanu P Perumal ,  Satheesh K Podaralla ,  Radhey S Kaushik

IPC: A61K9/14 ,  A61K47/48 ,  B82Y5/00 ,  C07K1/113 ,  A61K9/16 ,  A61K31/704 ,  A61K31/713 ,  A61K31/721 ,  A61K47/42

CPC classification number: A61K9/14 ,  A61K9/1682 ,  A61K31/704 ,  A61K31/713 ,  A61K31/721 ,  A61K47/42 ,  A61K47/60 ,  B82Y5/00 ,  C07K1/1136

Abstract: Methods are described for producing non-immunogenic nanoparticles from protein sources by controlling the pH in a nanoprecipitation process. The nanoparticles that are produced by the disclosed methods range in diameter size from about 100 ran to about 400 nm, with a preferred diameter size of from approximately 100 nm to approximately 300 nm, thereby rendering them non-immunogenic. The invention further discloses methods for producing nanoconjugates that are suitable for a variety of therapeutic, diagnostic and other uses.

公开(公告)号：US20160367683A1

公开(公告)日：2016-12-22

申请号：US14743717

申请日：2015-06-18

Applicant: South Dakota State University

Inventor： Hemachand Tummala ,  Pratik Muley

IPC: A61K47/48 ,  A61K9/00 ,  A61K35/14 ,  A61K49/00

CPC classification number: A61K35/14 ,  A61K47/6929

Abstract: The present invention relates to the production of modified microscale and nanoscale particles that have enhanced in vivo delivery characteristics. The resultant particles can be used in any of a number of applications including informatics, detection, diagnosis, imaging, and/or therapeutics. Further, the modified particles of the present invention have enhanced circulation half time and elimination rate constant characteristics, and enhanced biodistribution.

Abstract translation: 本发明涉及具有增强的体内递送特征的改性微米级和纳米尺寸颗粒的生产。 所得颗粒可用于许多应用，包括信息学，检测，诊断，成像和/或治疗。 此外，本发明的改性颗粒具有增强的循环半衰期和消除速率常数特征，并且增强了生物分布。

公开(公告)号：US20160322174A1

公开(公告)日：2016-11-03

申请号：US14701125

申请日：2015-04-30

Applicant: South Dakota State University

Inventor： Qi Hua Fan ,  Mukul Kumar Dubey ,  Zhengrong Gu

IPC: H01G11/34 ,  H01G11/38 ,  H01G11/86 ,  C01B31/08 ,  B01J19/08

CPC classification number: H01G11/34 ,  B01J19/088 ,  B01J2219/0809 ,  B01J2219/0828 ,  B01J2219/083 ,  B01J2219/0833 ,  B01J2219/0835 ,  B01J2219/0879 ,  C01B32/366 ,  H01G11/38 ,  H01G11/86

Abstract: A method for using plasma to activate biochar is disclosed where reactive gas(es) are excited by external power; biochar set on a sample holder is electrically biased or set at a floating potential so that charged particles of a certain type are attracted to the biochar, leading to intensive chemical reactions.

Abstract translation: 公开了一种使用等离子体激活生物炭的方法，其中反应性气体被外部电力激发; 设置在样品架上的生物炭被电偏置或设置为浮动电位，使得某种类型的带电粒子被吸引到生物炭，导致强烈的化学反应。

公开(公告)号：US20160317638A1

公开(公告)日：2016-11-03

申请号：US15105195

申请日：2014-12-17

Applicant: THE JOHNS HOPKINS UNIVERSITY ,  SOUTH DAKOTA STATE UNIVERSITY

Inventor： David A. Sack ,  Weiping Zhang

IPC: A61K39/108 ,  A61K45/06 ,  A61K39/08 ,  C07K14/245

CPC classification number: A61K39/0258 ,  A61K39/08 ,  A61K45/06 ,  A61K2039/575 ,  A61K2039/6037 ,  C07K14/245 ,  C07K2319/00 ,  C07K2319/40 ,  C07K2319/55 ,  Y02A50/474

Abstract: Provided herein are polypeptides comprising up to 9 antigenic elements of ETEC virulence determinants: 7 CFA adhesins [CFA/I, CFA/II (CS1, CS2, CS3), CFA/IV (CS4, CS5, CS6)] expressed by the most prevalent and virulent ETEC strains, and 2 toxins expressed by all ETEC strains, were genetically fused together for CFA-toxoid fusion with proteins (CFA/I/II/IV-STa-toxoidLTtoxoid). Methods for making these polypeptides and their use in the treatment of ETEC related disease are also provided.

Abstract translation: 本文提供了包含多达9个ETEC毒力决定簇的抗原性元件的多肽：由最流行的表达的7个CFA粘附素[CFA / I，CFA / II（CS1，CS2，CS3），CFA / IV（CS4，CS5，CS6）] 并且所有ETEC菌株表达的毒素ETEC菌株和2种毒素被遗传融合在一起，用于与蛋白质（CFA / I / II / IV-STa-类毒素类毒素）的CFA-类毒素融合。 还提供了制备这些多肽的方法及其在治疗ETEC相关疾病中的用途。